Introduction
NSCLC, tumor, Esophageal squamous cell carcinoma, Esophageal cancer, Cancer
TUMOR, RECURRENCE, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, MALIGNANT TUMORS, NSCLC, ESOPHAGEAL CANCER, CANCER
Esophageal cancer (EC) is a major tumor, and its morbidity and mortality are at the forefront of malignant tumors. Esophageal squamous cell carcinoma accounts for more than 95% of cases in China, most of which are found in the middle and late stages (For patients with recurrence after surgery, the 2016 Union for International Cancer Control (NCCN) guidelines recommend chemoradiotherapy as the standard treatment, and fluorouracil- or taxane-based chemoradiotherapy is recommended as the preferred regimen. However, due to the lack of evidence, there is no unified standard for the radiotherapy target area and dose (In recent years, some studies have shown that radiotherapy or chemotherapy can enhance the efficacy of immune checkpoint inhibitors by destroying the genome of tumor cells and enhancing immunogenicity. CRT+ immune-maintenance therapy has become the standard treatment for locally advanced NSCLC. However, there is still a lack of evidence in the field of EC.Based on the above theory and clinical practice, we conducted a phase Ib/II study of immunotherapy after chemoradiotherapy for recurrent EC, aiming to verify the efficacy and safety of this treatment mode, analyze the therapeutic effect, and explore the biomarkers related to the efficacy.